Treatments for stage B liver cancer
The following are treatment options for stage B liver cancer. Your healthcare team will suggest treatments based on your needs and work with you to develop a treatment plan.
Transarterial chemoembolization (TACE) @(Model.HeadingTag)>
TACE is a treatment that blocks the blood supply to a liver tumour and delivers chemotherapy directly to the tumour. It is the standard treatment for people who have good liver function, have a good
Targeted therapy @(Model.HeadingTag)>
Targeted therapy uses drugs to treat specific molecules (such as proteins) on cancer cells or inside them. By targeting these molecules, the drugs stop the growth and spread of cancer cells while limiting harm to normal cells. The targeted therapy drugs used for stage B liver cancer are sorafenib (Nexavar) and lenvatinib (Lenvima).
Targeted therapy may be offered if you cannot have TACE because you have portal hypertension or portal vein thrombosis or if TACE did not work.
Radiation therapy @(Model.HeadingTag)>
The following radiation therapy treatments may be offered if you are not able to have TACE.
Transarterial radioembolization (TARE) is a treatment that blocks the blood supply to a liver tumour and delivers radiation directly to the tumour.
Stereotactic body radiation therapy (SBRT) is a type of radiation therapy that delivers very focused beams of high-dose radiation to liver tumours.
Clinical trials @(Model.HeadingTag)>
Talk to your doctor about clinical trials open to people with liver cancer in Canada. Clinical trials look at new ways to prevent, find and treat cancer. Find out more about clinical trials.
Expert review and references
Kelly W Burak, MD, FRCPC, MSc(Epid)
Vincent Tam, BSc(Hon), MD, FRCPC
Burak KW, Sherman M. Hepatocellular carcinoma: consensus, controversies and future directions: a report from the Canadian Association for the Study of the Liver hepatocellular carcinoma meeting. Canadian Journal of Gastroenterology and Hepatology. 2015: 29(4):178–184. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444026/.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology. 2018: 69:182–236. https://www.journal-of-hepatology.eu/article/S0168-8278(18)30215-0/fulltext.
Heimback JK, Kulik LM, Finn RS, et al . AASLD guidelines for the treatment of hepatocellular carcinoma . Hepatology . 2017 : 67(1):358–380 .
Marrero JA, Kulik LM, Sirlin CB, et al . Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases . Hepatology . 2018 : 68(2):723–750 .
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers (Version 3.2021). 2021.